Does Nebulized 3% Hypertonic Saline Shorten the Duration of Hospitalization in Preschool Children with Acute Wheezing?

Effectiveness of nebulized 3% hypertonic Saline in hospitalized preschool children with acute wheezing: A prospective, randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20170327001

Enrollment

Registered

2017-03-27

Start date

2016-07-05

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preschool wheezing hypertonic saline preschool wheezing length of stay randomized controlled trial

Interventions

participants will receive nebulized salbutamol 2.5 mg + 3% hypertonic saline solution 3.5 ml ,participants will receive nebulized salbutamol 2.5 mg + normal saline solution 3.5 ml

Active Comparator Drug,Placebo Comparator Drug

hypertonic saline group,normal saline group

Eligibility

Sex/Gender

All

Age

6 Weeks to 5 Years

Inclusion criteria

Inclusion criteria: Children with acute wheezing Aged 6 weeks to 5 years Admitted to King Chulalongkorn Memorial Hospital

Exclusion criteria

Exclusion criteria: Heart disease Chronic lung disease Asthma Current steroid usage

Design outcomes

Primary

Measure	Time frame
length of hospital stay when patient was ready to discharge days	—

Secondary

Measure	Time frame
improvement of clinical every 12 hr during study asthma clinical severity score ,oxygen therapy every 12 hr during study days	—

Countries

Thailand

Contacts

Public ContactThanakorn Kanjanapradap

Chulalongkorn university

thanakornmd@gmail.com0810559229

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026